Deirdre A Lum1, Eric R Sokol2, Jonathan S Berek2, Jay Schulkin3, Ling Chen4, Cora-Ann McElwain3, Jason D Wright4. 1. Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, California. Electronic address: lumd@stanford.edu. 2. Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, California. 3. American College of Obstetricians and Gynecologists, Washington, DC. 4. Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, NY.
Abstract
STUDY OBJECTIVE: To determine whether members of the AAGL Advancing Minimally Invasive Gynecologic Surgery Worldwide (AAGL) and members of the American College of Obstetricians and Gynecologists Collaborative Ambulatory Research Network (ACOG CARN) have changed their clinical practice based on the 2014 Food and Drug Administration (FDA) warnings against power morcellation. DESIGN: A survey study. SETTING: Participants were invited to complete this online survey (Canadian Task Force classification II-2). PATIENTS: AAGL and ACOG CARN members. INTERVENTIONS: An online anonymous survey with 24 questions regarding demographics and changes to clinical practice during minimally invasive myomectomies and hysterectomies based on the 2014 FDA warnings against power morcellation. MEASUREMENTS AND MAIN RESULTS: A total of 615 AAGL members and 54 ACOG CARN members responded (response rates of 8.2% and 60%, respectively). Before the FDA warnings, 85.8% and 86.9%, respectively, were using power morcellation during myomectomies and hysterectomies. After the FDA warnings, 71.1% and 75.8% of respondents reported stopping the use of power morcellation during myomectomies and hysterectomies. The most common reasons cited for discontinuing the use of power morcellation or using it less often were hospital mandate (45.6%), the concern for legal consequences (16.1%), and the April 2014 FDA warning (13.9%). Nearly half of the respondents (45.6%) reported an increase in their rate of laparotomy. Most (80.3%) believed that the 2014 FDA warnings have not led to an improvement in patient outcomes and have led to harming patients (55.1%). CONCLUSION: AAGL and ACOG CARN respondents reported decreased use of power morcellation during minimally invasive gynecologic surgery after the 2014 FDA warnings, the most common reason cited being hospital mandate. Rates of laparotomy have increased. Most members surveyed believe that the FDA warnings have not improved patient outcomes.
STUDY OBJECTIVE: To determine whether members of the AAGL Advancing Minimally Invasive Gynecologic Surgery Worldwide (AAGL) and members of the American College of Obstetricians and Gynecologists Collaborative Ambulatory Research Network (ACOG CARN) have changed their clinical practice based on the 2014 Food and Drug Administration (FDA) warnings against power morcellation. DESIGN: A survey study. SETTING:Participants were invited to complete this online survey (Canadian Task Force classification II-2). PATIENTS: AAGL and ACOG CARN members. INTERVENTIONS: An online anonymous survey with 24 questions regarding demographics and changes to clinical practice during minimally invasive myomectomies and hysterectomies based on the 2014 FDA warnings against power morcellation. MEASUREMENTS AND MAIN RESULTS: A total of 615 AAGL members and 54 ACOG CARN members responded (response rates of 8.2% and 60%, respectively). Before the FDA warnings, 85.8% and 86.9%, respectively, were using power morcellation during myomectomies and hysterectomies. After the FDA warnings, 71.1% and 75.8% of respondents reported stopping the use of power morcellation during myomectomies and hysterectomies. The most common reasons cited for discontinuing the use of power morcellation or using it less often were hospital mandate (45.6%), the concern for legal consequences (16.1%), and the April 2014 FDA warning (13.9%). Nearly half of the respondents (45.6%) reported an increase in their rate of laparotomy. Most (80.3%) believed that the 2014 FDA warnings have not led to an improvement in patient outcomes and have led to harming patients (55.1%). CONCLUSION: AAGL and ACOG CARN respondents reported decreased use of power morcellation during minimally invasive gynecologic surgery after the 2014 FDA warnings, the most common reason cited being hospital mandate. Rates of laparotomy have increased. Most members surveyed believe that the FDA warnings have not improved patient outcomes.
Keywords:
American Association of Gynecologic Laparoscopists; American College of Obstetricians and Gynecologists; Food and Drug Administration warning; Power morcellation; Survey
Authors: Francesco Multinu; Jvan Casarin; Kristine T Hanson; Stefano Angioni; Andrea Mariani; Elizabeth B Habermann; Shannon K Laughlin-Tommaso Journal: JAMA Surg Date: 2018-06-20 Impact factor: 14.766
Authors: Erika L Mowers; Courtney S Lim; Bethany Skinner; Nichole Mahnert; Sara R Till; Sawsan As-Sanie Journal: JSLS Date: 2017 Jul-Sep Impact factor: 2.172
Authors: Lukas van den Haak; Cor D de Kroon; Milo I Warmerdam; Albert G Siebers; Johann P Rhemrev; Theodoor E Nieboer; Frank Willem Jansen Journal: Arch Gynecol Obstet Date: 2018-11-30 Impact factor: 2.344
Authors: Michael Anapolski; Anja Schellenberger; Ibrahim Alkatout; Dimitrios Panayotopoulos; Alexander Gut; Stefan Soltesz; Sven Schiermeier; Thomas Papathemelis; Günter K Noé Journal: Sci Rep Date: 2021-10-22 Impact factor: 4.379
Authors: Michael G Tal; Ran Keidar; Gilad Magnazi; Ohad Henn; Jin Hee Kim; Scott G Chudnoff; Kevin J Stepp Journal: Reprod Sci Date: 2022-08-08 Impact factor: 2.924